The prevalence of nonalcoholic steatohepatitis (NASH), a progressive type of fatty liver disease, appears to be on the rise in adolescents, increasing four-fold between 1988 and 2010, according to...

Particular eating behaviors may lower the risk of developing non-alcoholic fatty liver disease (NAFLD), according to research presented this week at The Liver Meeting® — held by the American...

UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, is proud to announce 16 CIMZIA® (certolizumab pegol) presentations at the 2016 American...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and...

Trimble (NASDAQ: TRMB) concluded its 8th International User Conference with more than 4,400 registered attendees representing over 80 countries. Dimensions 2016 provided insight into how...